208 related articles for article (PubMed ID: 25637330)
1. Incidence and risk of xerosis with targeted anticancer therapies.
Valentine J; Belum VR; Duran J; Ciccolini K; Schindler K; Wu S; Lacouture ME
J Am Acad Dermatol; 2015 Apr; 72(4):656-67. PubMed ID: 25637330
[TBL] [Abstract][Full Text] [Related]
2. Skin moisturization for xerosis related to targeted anticancer therapies.
Gisondi P; Girolomoni G
J Am Acad Dermatol; 2015 Jul; 73(1):e33. PubMed ID: 26089072
[No Abstract] [Full Text] [Related]
3. Reply to: "Skin moisturization for xerosis related to targeted anticancer therapies".
Valentine J; Belum VR; Duran J; Ciccolini K; Schindler K; Wu S; Lacouture ME
J Am Acad Dermatol; 2015 Jul; 73(1):e35-6. PubMed ID: 26089073
[No Abstract] [Full Text] [Related]
4. Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis.
Ensslin CJ; Rosen AC; Wu S; Lacouture ME
J Am Acad Dermatol; 2013 Nov; 69(5):708-720. PubMed ID: 23981682
[TBL] [Abstract][Full Text] [Related]
5. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis.
Minkis K; Garden BC; Wu S; Pulitzer MP; Lacouture ME
J Am Acad Dermatol; 2013 Sep; 69(3):e121-8. PubMed ID: 23357570
[TBL] [Abstract][Full Text] [Related]
6. Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.
Belum VR; Washington C; Pratilas CA; Sibaud V; Boralevi F; Lacouture ME
Pediatr Blood Cancer; 2015 May; 62(5):798-806. PubMed ID: 25683226
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies.
Santoni M; Guerra F; Conti A; Lucarelli A; Rinaldi S; Belvederesi L; Capucci A; Berardi R
Cancer Treat Rev; 2017 Sep; 59():123-131. PubMed ID: 28818671
[TBL] [Abstract][Full Text] [Related]
8. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis.
Abdel-Rahman O; ElHalawani H; Fouad M
Future Oncol; 2015; 11(17):2471-84. PubMed ID: 26274495
[TBL] [Abstract][Full Text] [Related]
9. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
Grávalos C; Sanmartín O; Gúrpide A; España A; Majem M; Suh Oh HJ; Aragón I; Segura S; Beato C; Botella R
Clin Transl Oncol; 2019 May; 21(5):556-571. PubMed ID: 30284232
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis.
Qi WX; Fu S; Zhang Q; Guo XM
J Cancer Res Ther; 2016; 12(2):775-81. PubMed ID: 27461650
[TBL] [Abstract][Full Text] [Related]
11. Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.
Dai J; Belum VR; Wu S; Sibaud V; Lacouture ME
J Am Acad Dermatol; 2017 Nov; 77(5):902-910.e2. PubMed ID: 28918974
[TBL] [Abstract][Full Text] [Related]
12. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis.
Garden BC; Wu S; Lacouture ME
J Am Acad Dermatol; 2012 Sep; 67(3):400-8. PubMed ID: 22088429
[TBL] [Abstract][Full Text] [Related]
13. Skin adverse events in recently approved targeted therapies in solid malignancies.
Habre M; Salloum A; Habre SB; Abi Chebl J; Dib R; Kourie HR
Future Oncol; 2019 Jan; 15(3):331-343. PubMed ID: 30523696
[TBL] [Abstract][Full Text] [Related]
14. Alopecia in patients treated with molecularly targeted anticancer therapies.
Belum VR; Marulanda K; Ensslin C; Gorcey L; Parikh T; Wu S; Busam KJ; Gerber PA; Lacouture ME
Ann Oncol; 2015 Dec; 26(12):2496-502. PubMed ID: 26387145
[TBL] [Abstract][Full Text] [Related]
15. Dermatological side effects of current and upcoming targeted therapies in oncology.
Bonny M; Buyse V; Brochez L
Acta Clin Belg; 2011; 66(2):97-103. PubMed ID: 21630605
[TBL] [Abstract][Full Text] [Related]
16. Risk of serious adverse event and fatal adverse event with molecular target anticancer drugs in cancer patients: A meta-analysis.
Wang Z; Yang X; Wang J; Wang S; Mao X; Li M; Zhao Y; Wang W; Qi X; Wu T
J Cancer Res Ther; 2019; 15(7):1435-1449. PubMed ID: 31939421
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Pulipati B; Chu D; Zhu X; Wu S
Am J Hypertens; 2010 May; 23(5):460-8. PubMed ID: 20186127
[TBL] [Abstract][Full Text] [Related]
18. Incidence and relative risk of hemorrhagic events associated with ramucirumab in cancer patients: a systematic review and meta-analysis.
Tian R; Yan H; Zhang F; Sun P; Zheng X; Zhu Y; Wang Q; He J
Oncotarget; 2016 Oct; 7(40):66182-66191. PubMed ID: 27507055
[TBL] [Abstract][Full Text] [Related]
19. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis.
Drucker AM; Wu S; Dang CT; Lacouture ME
Breast Cancer Res Treat; 2012 Sep; 135(2):347-54. PubMed ID: 22782294
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
Crit Rev Oncol Hematol; 2015 Jun; 94(3):323-36. PubMed ID: 25749417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
